Nestle Health Science has licensed a protein engineering platform from Codexis in a $14m deal that includes an option to co-develop a phenylketonuria drug candidate called CDX-6114.
Pfizer is building a $200m (€179m) R&D centre in Chesterfield, Missouri at which it will consolidate biotherapeutics process development operations in the region.
Researchers define action profile of Bial compound
Experts are calling for an increased focus on human cellular model development after animal tests failed to detect the toxicity of an experimental drug before the first-in-human clinical trial that left one dead.
Sekisui XenoTech has added new dermal subcellular fraction test systems to its contract research services.
The “NCI Formulary” enables investigators to obtain investigational agents for testing in new preclinical or clinical studies.
A revised concept paper on first-in-human trials will be ready next month according to the EMA which is reviewing the French Phase I trial in which one volunteer died in January.
HemoShear Therapeutics has teamed up with Pfizer to develop a predictive model for preclinical drug-induced vascular injury (DIVI).
Merck & Co. has expanded a partnership to use Emulate’s organ-on-chip technology to carry out predictive modelling of inflammatory processes.
China’s ShangPharma is building a $60m (€53m) single-use biologics manufacturing plant in Qidong, to be operated by its CMO subsidiary.
The US spends billions on preclinical research that cannot be replicated due to errors in design, problems with lab protocols and mistakes during data analysis according to new research.
Mid-size and large sponsors foresee increases in RFP (request for proposal) volume for outsourced clinical services across all phases through December 2014, especially for larger CROs, according to a new report.
Crown Bioscience has teamed up with Shin Nippon Biomedical Laboratories (SNBL) to navigate obstacles in the Japanese outsourcing market.
China’s top CRO Wuxi Apptec has purchased a remote clinical trial monitoring tool that will allow its toxicology clients log onto a secure Web site to view data from on-going studies.
Ambrx and Zhejiang Medicine have selected Wuxi to accelerate the development of a potential ADC (antibody drug conjugate) targeting Her2-positive breast cancer.
Covance’s 10 percent growth in Q1 2013 compared to the same quarter last year was driven mostly by its central laboratories business and has caused a boost in its revenue targets for the rest of the year.
Goodwin Biotechnology has teamed up with Coldstream Laboratories to offer clients ADC services as another example of biopharma demand driving contract manufacturing and development.
An uptick in the outsourcing of preclinical trials is expected as pharmaceutical companies look to restructure and cut costs, but that increase won't necessarily begin in 2013, according to an analyst.
Merck & Co and Lycera have signed a preclinical research deal that could be worth up to $300m if certain milestones are met.
Demand for improved bioavailability solutions will drive drug delivery dealmaking in 2013 according to a pharmaceutical industry expert.
CMOs and Pharmas will own the manufacturing processes developed at a new facility as part of an ‘open source’ ethos Merck Millipore has introduced.
Outsourcing-Pharma presents a round of new contract manufacturing deals, including business wins for Boehringer, Jubilant and Scynexis.
Charles River wants to buy drug discovery assets to meet interest in strategic outsourcing of non-regulated efficacy testing.
BioTox scoops Bio-Quant as Apricus off-loads preclinical sectors
BioTox Sciences is flexing its drug discovery and preclinical testing muscle after acquiring Bio-Quant from its owner Apricus Biosciences.
CIT to buy Canada’s LAB Research
French preclinical contract research organisation (CRO) CIT has said it will buy Canadian counterpart LAB Research in a deal that would rescue the Quebec-based firm from the receivers.
Merck ends discovery deal with Galapagos
US drug giant Merck & Co has ended its strategic drug discovery and development alliance with Belgian biotechnology firm Galapagos.
RXi Pharmaceuticals has applied its sd-rxRNA to dermal cells, establishing the efficacy of the technology as it seeks to move it on to the next stage of development, a company VP told in-PharmaTechnologist.
URMC forms group to help biotechs with translational research
URMC has set up the Center for Human Experimental Therapeutics (CHET) to help biotechs and academics advance product candidates from preclinical studies into trials in human.
GE Healthcare launches FTA DMPK sample cards
GE Healthcare says its new range of sample collection cards reduce sample volumes needed for drug metabolism across pharmacokinetics (DMPK) in all stages of drug development process.
Patheon adds development services at Italian plant
Canadian CMO Patheon has set up a pharmaceutical development services (PDS) sterile products suite at its manufacturing facility in Ferentino, Italy.
ethica thinks Matrix' data analysis tool is good eidyia
ethica Clinical has added biomarker data analysis technology to its roster of services in a C$1.25m (€782,899) deal with fellow Canadian CRO Matrix Pharma.
Xybion and Locus team up on animal and preclinical data management
US firms Xybion Medical Systems and Locus Technology say their new animal management and data analysis partnership will help streamline preclinical development and reduce research costs.
Nanotech deal to boost oral bioavailability
Yissum is collaborating with Aurum, Ventures MKI to develop a nanotechnology controlled release delivery platform, which is designed to increase the bioavailability of orally administered lipophilic drugs.
Cell Therapeutics seeks to offload preclinical unit
Seattle, US-based Cell Therapeutics Inc is looking at ways to reduce its involvement in a preclinical research facility based in Bresso, Italy, as it tries to cut costs.
WuXi, Covance split before deal is consummated
The much-trumpeted partnership between China’s WuXi PharmaTech and Covance to provide ‘world class preclinical research services’ has been called off.
Lilly forges multi million dollar supply chain deal
BioConvergence has forged a 'significant' supply chain
partnership with Eli Lilly, worth millions of dollars over ten
New China:US preclinical partnership formed
US-based MPI Research and China's Shanghai Medicilon have formed a
joint venture in preclinical services, as they position themselves
to cash in on what is a budding market sector in China.
French CROs have eye on niche market
Two French contract research organisations (CROs) that specialise
in ophthalmology have banded together to offer specialised services
to this niche market.
Legumes encapsulate oral antifungal drug
US-based drug delivery firm, BioDelivery Sciences International
(BDSI), has asked for approval to start clinical trials of a soya
bean-based delivery technology that would lead to the first oral
version of amphotericin B, a widely-used...
SAFC services sought by French biotech
SAFC will provide chemical development services for a new cancer
treatment belonging to French biotech firm Affichem.
Merck tests India's outsourcing capabilities
US-based drug maker Merck, has agreed to outsource some of its
preclinical trial work to an Indian-based company, marking the
first time the pharma giant has used an Indian company to conduct
Covance scores biggest-ever contract
World-leading clinical research organisation (CRO) Covance has
scored what it says is the biggest contract in its history - a
dedicated space agreement worth a minimum of $187m (€149m).
UK National Biomanufacturing Centre on track for '06 start-up
Construction of the UK National Biomanufacturing Centre, an
ambitious project aimed at helping biotechnology start-ups get
their product ideas into clinical trials, is progressing on
schedule and should be ready to start production...
Skyepharma licenses yeast encapsulation tech
Microencapsulation specialist Micap has made its first foray into
the pharmaceutical sector after clinching a licensing deal with UK
drug delivery specialist SkyePharma.
Yeast encapsulator makes progress
Micap, which specialises in using yeast and other organisms as
microcapsules for protecting active compounds, is set to expand its
business after extricating itself from an 'onerous' license with
Cobra signs cancer vaccine production deal
Cobra Biomanufacturing has signed an agreement to supply Advaxis
with clinical and commercial supplies of its Listeria
monocytogenes-based cancer vaccine.